In 2024 the Food and Drug Administration added cardiovascular risk as a reason to be prescribed the GLP-1 drug Wegovy, grounded in results from a major trial that showed fewer heart attacks, strokes, and cardiovascular deaths in adults with obesity or overweight and established heart disease
Roles of inflammatory and anabolic cytokines in cartilage metabolism: signals and multiple effectors converge upon Mmp-13 regulation in osteoarthritis
Its important to talk to your healthcare provider before making any changes to your diabetes treatment plan
Challenges with Access, Costs, and Supply Despite the promise of weight loss drugs, challenges remain
At 40 weeks, mean HbA1c levels for Mounjaro patients at doses of 5 mg, 10 mg, and 15 mg were reduced by 2.01%, 2.24%, and 2.30%, respectively, compared to a reduction of 1.86% with Ozempic 1 mg